CD19 and neoplasm: The main mechanisms of escape from CD19 CAR-T therapy in heterogeneous tumors include the outgrowth of pre-existing or newly evolved CD19-negative subclones and impaired CAR-T cell cytotoxicity due to T-cell exhaustion or suppression within the tumor microenvironment.